Sydney

NANOCELLE “ISSUE OF ALLOWANCE” BY US PATENT OFFICE

Retrieved on: 
Wednesday, October 6, 2021

With this Patent now allowed/granted it has cleared several barriers for partnering discussions.

Key Points: 
  • With this Patent now allowed/granted it has cleared several barriers for partnering discussions.
  • This announcement was authorised by the Board of Directors of Medlab Clinical Limited.
  • Medlabs pipeline comprises a number of small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies.
  • NanoCelle, the patented delivery platform is wholly owned by Medlab and developed in Medlabs owned OGTR Registered Laboratory.

Gennix Crypto Lending Platform Earns ‘Secure’ Audit Score for its Smart-Contract

Retrieved on: 
Tuesday, October 5, 2021

Gennix provides its users with yield-farming opportunities with a promotional APY on the farming and staking of digital assets listed on its lending platform of up to 1000% APY.

Key Points: 
  • Gennix provides its users with yield-farming opportunities with a promotional APY on the farming and staking of digital assets listed on its lending platform of up to 1000% APY.
  • Gennix also offers attractive borrowing and lending rates and supports NFT yield boosters, which will enable users to accumulate more capital in a safe and secure manner.
  • In result, Gennix came through each process and passed its overall audit, across all verticals; and the AntiHACK smart-contract audit report concluded that Gennix's overall system and platform are secured, reliable and compliant with industry standards.
  • Gennix also features integrated blacklisting capabilities for enhanced security and to foster confidence in the lender(s) on its platform.

Recce Pharmaceuticals Announces RECCE® 327 Registered in the Australian New Zealand Clinical Trials Registry for Phase I Intravenous Clinical Trial

Retrieved on: 
Monday, October 4, 2021

SYDNEY, Australia, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE) (FSE:R9Q) (Company), the Company developing new classes of synthetic anti-infectives, is pleased to announce the trial registration for its lead compound, RECCE 327 (R327), in the Australian New Zealand Clinical Trial Registry (ANZCTR) for a Phase I intravenous (IV) clinical trial under the trial ID ACTRN12621001313820p.

Key Points: 
  • SYDNEY, Australia, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE) (FSE:R9Q) (Company), the Company developing new classes of synthetic anti-infectives, is pleased to announce the trial registration for its lead compound, RECCE 327 (R327), in the Australian New Zealand Clinical Trial Registry (ANZCTR) for a Phase I intravenous (IV) clinical trial under the trial ID ACTRN12621001313820p.
  • The ANZCTR is an online registry of clinical trials being undertaken in Australia, New Zealand and elsewhere.
  • The ANZCTR includes trials from the full spectrum of therapeutic areas of pharmaceuticals.
  • This registration represents one of the final administrative stages for the Phase I clinical trial of R327 to commence.

SyncDAO Creates New Entrepreneurial Opportunities in Blockchain

Retrieved on: 
Friday, October 1, 2021

Cofounder of SyncDAO Paul Holland saw the biggest hurdle with DeFi mass adoption would come from a flaw in its design of cutting out the middlemen.

Key Points: 
  • Cofounder of SyncDAO Paul Holland saw the biggest hurdle with DeFi mass adoption would come from a flaw in its design of cutting out the middlemen.
  • By creating a way for referrers to earn an ongoing income for introducing new users, SyncDAO is creating entrepreneurial opportunities and helping to pave the way for the DeFi movement to become mainstream Holland says.
  • Through the SyncDAO affiliate smart contract layer, anyone can be rewarded for referring new users to the Perpetual Vaults.
  • This is all managed in a permissionless manner through fully audited smart contracts on the Ethereum blockchain.

Immutep to Present Phase II TACTI-002 Data at SITC 2021

Retrieved on: 
Friday, October 1, 2021

As previously announced, final Overall Survival data from Immuteps Phase IIb AIPAC will also be presented at SITC 2021 as a late breaker poster presentation.

Key Points: 
  • As previously announced, final Overall Survival data from Immuteps Phase IIb AIPAC will also be presented at SITC 2021 as a late breaker poster presentation.
  • SITC is the worlds leading member-driven organisation specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.
  • The trial is a Phase II, Simons two-stage, non-comparative, open-label, single-arm, multicentre clinical study that is taking place in study centres across Australia, Europe, the UK and US.
  • Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Immutep Receives A$3.4 million R&D Tax Incentive from French Government

Retrieved on: 
Wednesday, September 29, 2021

The Crdit dImpt Recherche (CIR), meaning Research Tax Credit, is a French government tax incentive by which French companies conducting research and development activities in Europe can be reimbursed 30% of their eligible expenditure.

Key Points: 
  • The Crdit dImpt Recherche (CIR), meaning Research Tax Credit, is a French government tax incentive by which French companies conducting research and development activities in Europe can be reimbursed 30% of their eligible expenditure.
  • Immutep qualifies to receive CIR tax incentive through its subsidiary Immutep S.A.S.
  • Immutep also qualifies for cash rebates from the Australian Federal Governments R&D tax incentive program in respect of expenditure incurred on eligible R&D activities conducted in Australia.
  • Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

The Inaugural Distinguished Gentleman's Drive Unites Thousands of Stylish Classic Car Drivers Around the World in Its First-Ever Charity Drive

Retrieved on: 
Wednesday, September 29, 2021

The eventraisedover $200,000 USD for its charity partnerMovember, which is the world's leading global organization focused solely on men's health.

Key Points: 
  • The eventraisedover $200,000 USD for its charity partnerMovember, which is the world's leading global organization focused solely on men's health.
  • The funds raised through The Distinguished Gentleman's Drive will be directed toward prostate cancer research and men's mental health programs.
  • Founder of The Distinguished Gentleman's Drive, Mark Hawwa, reflects on the inaugural event.
  • The Distinguished Gentleman's Ride unites classic and vintage style motorcycle riders all over the world to raise funds and awareness for prostate cancer research and men's mental health.

Immutep to Present at Healthcare Investor Conferences

Retrieved on: 
Tuesday, September 28, 2021

Sydney, AUSTRALIA, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, will present at investor conferences, as outlined below.

Key Points: 
  • Sydney, AUSTRALIA, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, will present at investor conferences, as outlined below.
  • Presenter: An informal discussion with Marc Voigt, CEO led by Goldman Sachs host Chris Cooper, Healthcare Analyst Global Investment Research and with investor Q&A.
  • Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease.
  • Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Immutep to Present Final Overall Survival Data From Phase IIb AIPAC as a Late Breaking Poster Presentation at SITC 2021

Retrieved on: 
Tuesday, September 21, 2021

The final OS data will be presented by Immutep at SITC 2021 as a late breaker poster presentation.

Key Points: 
  • The final OS data will be presented by Immutep at SITC 2021 as a late breaker poster presentation.
  • Interim OS data from the trial was presented in a spotlight presentation at the San Antonio Breast Cancer Symposium in December 2020.
  • Immutep will make the poster available on its website following publication at SITC 2021 and will host a webinar for investors after the conference.
  • SITC is the worlds leading member-driven organisation specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.

Crown Group transforming Eastlakes and creating Sydney’s ‘New East’

Retrieved on: 
Wednesday, September 15, 2021

Sydney, Australia, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Leading international property developer, Crown Group is in the midst of transforming one of the most little-known eastern suburbs, Eastlakes, creating what theyve dubbed the new east a $1billion thriving, vibrant, sophisticated lifestyle precinct, developed in two stages, The Grand Eastlakes (formerly known as Eastlakes LIVE).

Key Points: 
  • Sydney, Australia, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Leading international property developer, Crown Group is in the midst of transforming one of the most little-known eastern suburbs, Eastlakes, creating what theyve dubbed the new east a $1billion thriving, vibrant, sophisticated lifestyle precinct, developed in two stages, The Grand Eastlakes (formerly known as Eastlakes LIVE).
  • Crown Group Chair & Group CEO Iwan Sunito said we are dramatically transforming the suburb of Eastlakes building a modern, new urban village which will breathe much-needed new life and energy, optimism and renewal into this tired yet brilliantly located suburb in Sydneys highly coveted east.
  • Mr Sunito said Crown Group is creating a world-class urban village and destination in its own right at Eastlakes attracting a whole new community to live, work, shop, exercise and dine with their loved ones, friends and family.
  • Crown Group is genuinely transforming Eastlakes which will be a game-changer for the local area.